標準的な乳がん分類では重要な違いを見落とす可能性（Standard breast cancer classification may overlook important differences）

2026-08-27 カロリンスカ研究所（KI）

＜関連情報＞

• https://news.ki.se/standard-breast-cancer-classification-may-overlook-important-differences
• https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00238-3/fulltext

HER2陰性乳がんにおけるエストロゲン受容体発現サブグループ別の患者特性、治療パターン、および生存率：集団ベースのコホート研究 Patient characteristics, treatment patterns, and survival across estrogen receptor expression subgroups in HER2-negative breast cancer: a population-based cohort study

Qiao Yang ∙ Ceren Boyaci ∙ Ioannis Zerdes ∙ Irma Fredriksson ∙ Xinsong Chen ∙ Johan Hartman ∙ et al.
The Lancet Regional Health – Europe  Published:August 26, 2026
DOI:https://doi.org/10.1016/j.lanepe.2026.101826

Summary

Background
Estrogen receptor (ER) low (1–9%) breast cancer (BC) often behaves like triple-negative BC, while ERhigh (≥60%) disease has a more favorable prognosis. However, tumors with ER expressing 10–59% represent a poorly defined patient population. In this nationwide cohort study, we aimed to describe real-world patient characteristics, treatment patterns and survival across the entire ER spectrum in Human Epidermal growth factor Receptor 2 (HER2)-negative BC.

Methods
We conducted a population-based cohort study of all women diagnosed with HER2-negative BC in Sweden (2007–2023), based on prospectively collected data. Tumors were stratified into five ER subgroups: ER^0% (ERzero), ER^1–9% (ERlow), ER^10–29% (ERmild), ER^30–59% (ERmod), and ER^60–100% (ERhigh). We evaluated overall survival (OS) by ER subgroups and treatment (chemotherapy [CT] and endocrine therapy [ET]) using Kaplan–Meier analysis and multivariable Cox regression.

Findings
We included 75,211 patients. Compared to the ERhigh subgroup, both the ERmild (adjusted HR [aHR] = 1.59, 95% confidence interval [CI]: 1.31–1.93) and ERmod (aHR = 1.31, 95% CI: 1.17–1.47) subgroups had significantly worse survival (both adjusted P [aP] < 0.001). Notably, ERmild patients had survival outcomes and molecular characteristics similar to those of ERlow and ERzero patients. Patients with ERmild (aHR = 0.46, 95% CI: 0.23–0.94, aP = 0.033) and ERmod (aHR = 0.60, 95% CI: 0.42–0.85, aP = 0.0046) tumors, CT + ET was associated with a lower risk of death than ETonly.

Interpretation
Our findings highlight the importance of assessment of ER-low, mild and moderate tumors (1–59%). Reporting ER as a percentage can provide additional biological insight in clinical decision-making.

Funding
This study received no external funding.